broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K33622447-066-01-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.898748 | 0.700808 | -0.014035 | 0.921238 | 0.003716 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000968 |
BRD-K35520305-001-16-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.004432 | -0.310932 | -0.032483 | 1 | 0.363294 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000968 |
BRD-K36627727-001-05-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.51508 | 0.889554 | 0.400597 | 0.855404 | 0.603685 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000968 |
BRD-K36788280-001-01-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.567399 | 0.002323 | -0.012389 | 0.782228 | 0.000223 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000968 |
BRD-K37379014-001-02-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.273342 | 0.466823 | 0.426028 | 0.683704 | 0.002649 | 0.014427 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000968 |
BRD-K38332599-001-01-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.756298 | 2.144869 | 0.242429 | 0.936133 | 0.787631 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000968 |
BRD-K38527262-300-01-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.211516 | 13.359195 | 0.672733 | 0.833515 | 1.186202 | 1.236064 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000968 |
BRD-K38852836-001-02-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.357765 | 9.620228 | 0.399877 | 0.797129 | 0.116693 | 0.132984 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000968 |
BRD-K39974922-001-04-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.952064 | -0.10529 | -0.063159 | 0.963075 | 9,556.529928 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000968 |
BRD-K41859756-001-06-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.356897 | 2.791431 | 0.504618 | 0.741689 | 0.050773 | 0.079483 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000968 |
BRD-K42495768-001-01-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.404831 | -0.154861 | -0.135655 | 0.833771 | 0.000132 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000968 |
BRD-K42805893-001-04-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.225611 | 2.193667 | 0.467914 | 0.896241 | 2.799315 | 3.680019 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000968 |
BRD-K42828737-001-03-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.83421 | 7.062438 | 0.022782 | 0.904035 | 0.020269 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000968 |
BRD-K42898655-001-01-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.000622 | -0.331281 | -0.103216 | 1 | 0.015012 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000968 |
BRD-K43389675-001-02-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.080813 | 1.738764 | 0.544358 | 0.762442 | 0.820266 | 0.907794 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000968 |
BRD-K44227013-001-06-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.011436 | 0.016015 | -0.015348 | 1 | 0.008742 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000968 |
BRD-K44408410-001-17-6 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.784806 | 0.210265 | 0.039262 | 0.907023 | 0.320122 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000968 |
BRD-K44827188-001-06-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.050786 | 0.033477 | -0.045843 | 1 | 0.001027 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000968 |
BRD-K46386702-001-02-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.876058 | -7.184111 | 0.188763 | 0.900563 | 1.467977 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000968 |
BRD-K49328571-001-15-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.445321 | 1.047094 | 0.3367 | 1 | 0.061598 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000968 |
BRD-K49350383-001-14-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.832689 | -1.185771 | -0.23449 | 0.932234 | 0.030854 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000968 |
BRD-K50010139-001-01-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.879817 | 0.03228 | -0.038736 | 1 | 0.025201 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000968 |
BRD-K51313569-001-07-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.769622 | 1.439188 | 0.134941 | 0.846482 | 0.015438 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000968 |
BRD-K51791723-003-01-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | -0.015017 | 0.522176 | 0.473782 | 0.727334 | 1.240013 | 1.171693 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000968 |
BRD-K51967704-001-03-6 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.326498 | 3.032874 | 0.353563 | 0.890439 | 2.068159 | 2.931869 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000968 |
BRD-K52313696-001-12-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.356776 | -0.043707 | -0.077453 | 1 | 0.043349 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000968 |
BRD-K53414658-001-08-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.114798 | -0.265689 | -0.028437 | 1 | 195.202341 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000968 |
BRD-K53972329-001-07-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.878273 | 0.721565 | -0.067576 | 0.919297 | 0.014186 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000968 |
BRD-K54256913-001-08-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.830821 | -0.603678 | 0.103319 | 0.92923 | 0.03219 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000968 |
BRD-K54955827-001-02-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.995755 | 0.254619 | 0.00024 | 0.997299 | 0.006657 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000968 |
BRD-K54997624-001-06-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.227005 | -0.955689 | 0.073525 | 0.971577 | 0.000238 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000968 |
BRD-K55187425-236-05-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.617457 | -0.033336 | -0.188486 | 0.818929 | 0.003153 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000968 |
BRD-K56343971-001-14-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.438899 | 4.617103 | 0.318489 | 0.895905 | 1.652421 | 2.605245 | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000968 |
BRD-K56981171-001-02-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.642373 | 6.27266 | 0.360553 | 1 | 0.680859 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000968 |
BRD-K57080016-001-15-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.588894 | 0.547938 | 0.290775 | 0.810332 | 0.1203 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000968 |
BRD-K57169635-001-04-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.001486 | -0.129125 | -0.020895 | 1 | 0.00548 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000968 |
BRD-K58435339-001-03-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.169416 | 0.981237 | 0.365687 | 0.735758 | 0.479076 | 0.730347 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000968 |
BRD-K58529924-001-01-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.199252 | 5.114565 | 0.616813 | 0.889843 | 2.788899 | 3.080276 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000968 |
BRD-K58550667-001-08-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.136998 | 8.283383 | 0.581242 | 0.826335 | 0.088652 | 0.092146 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000968 |
BRD-K59317601-001-05-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.279013 | 1.786114 | 0.235773 | 0.734803 | 0.281937 | 0.445335 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000968 |
BRD-K59369769-001-22-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.852444 | 1.628681 | 0.136034 | 0.936523 | 0.153876 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000968 |
BRD-K60866521-001-07-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.789063 | -1.207763 | 0.097739 | 0.947342 | 0.006572 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000968 |
BRD-K60997853-001-02-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.590079 | 3.406339 | 0.259224 | 0.771878 | 0.045136 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000968 |
BRD-K61192372-001-08-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 2.21579 | 2.748382 | 0.29802 | 1 | 10.351901 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000968 |
BRD-K62008436-001-23-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.34313 | 5.311502 | 0.120183 | 0.70208 | 0.00766 | 0.009528 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000968 |
BRD-K62196610-001-01-6 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.276299 | 3.279041 | 0.14984 | 1 | 0.156211 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000968 |
BRD-K62200014-003-10-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.404522 | 0.084201 | 0.008703 | 0.726718 | 0.567114 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000968 |
BRD-K62391742-001-09-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.493328 | 0.363185 | 0.088363 | 0.796861 | 0.30862 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000968 |
BRD-K62627508-001-01-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.245435 | 1.246304 | 0.871951 | 0.61604 | 0.071646 | 0.12315 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000968 |
BRD-K63504947-001-14-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.956281 | 0.077691 | -0.041782 | 0.973597 | 0.000321 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000968 |
BRD-K63712959-001-01-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.254146 | 0.017117 | -0.012139 | 1 | 21.068153 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000968 |
BRD-K64052750-001-22-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.07013 | -0.18039 | -0.028811 | 1 | 12.311996 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000968 |
BRD-K64881305-001-03-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.312264 | 3.038972 | 0.827767 | 0.511521 | 0.010149 | 0.014009 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000968 |
BRD-K66175015-001-12-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.038844 | 1.606993 | 0.322203 | 0.924917 | 5.827972 | 6.128895 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000968 |
BRD-K67844266-003-01-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.083461 | 0.578809 | 0.772778 | 0.634196 | 0.237706 | 0.325887 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000968 |
BRD-K69001009-001-02-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.034643 | 0.858328 | 0.702415 | 0.782296 | 1.357168 | 1.475602 | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000968 |
BRD-K69694239-001-02-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.209316 | 0.985213 | 0.078026 | 0.740991 | 0.434842 | 0.754078 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000968 |
BRD-K69776681-001-03-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.638597 | 0.026365 | -0.018625 | 0.808607 | 0.000868 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000968 |
BRD-K70301465-001-05-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.344821 | 0.256774 | 0.091008 | 1 | 0.496713 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000968 |
BRD-K70401845-001-15-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.052195 | -0.156718 | -0.03527 | 1 | 0.372102 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000968 |
BRD-K73838513-003-05-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | -0.095199 | 1.391617 | 0.486088 | 0.901546 | 5.38381 | 4.750048 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000968 |
BRD-K74514084-003-09-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.312487 | 2.233399 | 0.365211 | 0.953727 | 5.858571 | 9.088777 | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000968 |
BRD-K76210423-001-01-6 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.007561 | 0.032467 | -0.000514 | 1 | 0.000639 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000968 |
BRD-K76239644-001-02-6 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.684034 | -2.199528 | 0.056219 | 0.933463 | 0.004684 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000968 |
BRD-K76674262-001-03-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.171941 | 2.306789 | 0.887592 | 0.501525 | 0.029029 | 0.034847 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000968 |
BRD-K76908866-001-07-6 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.016588 | 0.066626 | -0.003474 | 1 | 0.005451 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000968 |
BRD-K77625799-001-07-7 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.595532 | -0.254188 | -0.070346 | 0.885781 | 0.001306 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000968 |
BRD-K78431006-001-15-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | -0.139686 | 3.60766 | 0.390179 | 0.952502 | 7.18109 | 6.707189 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000968 |
BRD-K79254416-001-21-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.786991 | 4.843001 | 0.42738 | 1 | 0.833811 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000968 |
BRD-K81016934-001-02-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.899894 | -0.422437 | -0.022233 | 0.968006 | 0.007488 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000968 |
BRD-K81418486-001-44-2 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | -0.048842 | 1.357386 | 0.462229 | 0.843727 | 2.633053 | 2.458313 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000968 |
BRD-K81473043-001-19-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.072899 | -0.09904 | -0.011325 | 1 | 0.004171 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000968 |
BRD-K82135108-001-04-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.610853 | 0.577331 | 0.22744 | 0.782416 | 0.040786 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000968 |
BRD-K82746043-001-19-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.247097 | 0.901449 | 0.85409 | 0.357266 | 0.001759 | 0.003748 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000968 |
BRD-K82818427-001-04-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.281675 | -0.011791 | -0.001563 | 1 | 303.803249 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000968 |
BRD-K83029223-001-01-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.386263 | 0.882398 | 0.551948 | 0.680266 | 0.003959 | 0.0212 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000968 |
BRD-K85402309-043-01-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.582767 | 0.114099 | 0.049183 | 0.809447 | 0.37172 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000968 |
BRD-K85606544-001-09-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.709587 | 0.00682 | -0.031824 | 0.859099 | 468.069512 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000968 |
BRD-K86118762-001-01-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.795916 | -0.362873 | 0.021901 | 0.888857 | 0.144281 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000968 |
BRD-K86972824-001-01-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.051504 | -0.099178 | -0.075627 | 1 | 5,884.881276 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000968 |
BRD-K87737963-001-06-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.494481 | 0.129316 | -0.034514 | 0.745567 | 0.070265 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000968 |
BRD-K87909389-003-03-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.06544 | 0.80177 | 0.793155 | 0.651254 | 0.284203 | 0.338536 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000968 |
BRD-K88510285-001-17-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.161237 | 8.001931 | 0.693475 | 0.611074 | 0.013225 | 0.013885 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000968 |
BRD-K89014967-001-04-3 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.425092 | 0.697187 | 0.496211 | 0.73301 | 0.113069 | 1.721354 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000968 |
BRD-K92441787-001-04-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.874599 | -0.205393 | 0.00271 | 0.910021 | 10.308955 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000968 |
BRD-K92723993-001-17-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 7.050336 | 0.75155 | 0.06065 | 1 | 630.103373 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000968 |
BRD-K95142244-001-01-5 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.401775 | 0.48522 | 0.036211 | 1 | 0.438119 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000968 |
BRD-K96123349-236-02-8 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.684769 | -1.934826 | -0.10248 | 0.84299 | 0.076659 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000968 |
BRD-K98572433-001-02-9 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.926414 | -2.043881 | -0.104802 | 0.9461 | 0.74739 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000968 |
BRD-K99113996-001-02-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.849922 | 0.274917 | 0.025103 | 0.927956 | 0.108895 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000968 |
BRD-K99616396-001-05-1 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.72605 | -0.353125 | -0.06439 | 0.883325 | 0.027567 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000968 |
BRD-K99749624-001-07-0 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 0.989188 | 0.102974 | -0.001422 | 0.994832 | 0.187092 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000968 |
BRD-M97302542-001-04-4 | ACH-000968 | COLO792_SKIN | MTS010 | 1 | 1.064508 | 0.275204 | 0.005505 | 1 | 0.407292 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000968 |
BRD-A25234499-001-19-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.887773 | -0.209542 | -0.006223 | 0.95419 | 0.011439 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000970 |
BRD-A70858459-001-01-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.815564 | -0.373577 | 0.047577 | 0.842875 | 22.025385 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000970 |
BRD-A74914197-001-02-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.883233 | 5.120817 | 0.7271 | 1 | 0.00395 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000970 |
BRD-K02113016-001-19-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.928882 | -1.094895 | -0.04394 | 0.991426 | 0.00146 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000970 |
BRD-K02130563-001-11-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.393635 | 7.130494 | -0.01638 | 0.6316 | 0.027501 | 0.034168 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000970 |
BRD-K03390685-001-01-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.544459 | 2.686912 | 0.353162 | 0.707379 | 0.019618 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000970 |
BRD-K03406345-001-21-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.722226 | -0.417226 | -0.191926 | 0.892822 | 0.018073 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000970 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.